Thank you for your patience while we migrated this blog to our new website, and prepared new evaluations of drug repurposing patents for publication.
Here is the first part of what you will see discussed in the December 2015 Special Issue of ASSAY and Drug Development Technology – a selection of the international drug repurposing patent applications that were published during the second quarter of 2015:
- WO/2015/044762 (Warzawski Uniwersytet Medyczny, Warszawa, Poland): Cefazolin for autoimmune diseases and leukemia
- WO/2015/046857 (Industry-Academic Cooperation Foundation, Yonsei University, Seoul, Korea): Metformin for benign thyroid disease
- WO/2015/049471 (Inventiva Pharma, Daix, France): Odiparcil, a discontinued antithrobotic for mucopolysaccharidoses
- WO/2015/053452 (Korea Institute of Bioscience and Biotechnology, Daejeon, Korea): Silmasertib for conditions involving misdirected splicing
- WO/2015/057724 (Nora Therapeutics, Inc., Palo Alto, Cal., USA): G-CSF for a pregnancy complication
- WO/2015/059114 (University degli Studi di Padova, Padova, Italy): Yellow fever vaccine for prevention of breast cancer
- WO/2015/065497 (Schutz JW): Montelukast for mild cognitive impairment caused by mold exposure
- WO/2015/068940 (Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea): Malaria drugs for osteoporosis
- WO/2015/069711 (Celgene Corp., Summit, NJ, USA): Apremilast prevents cytokine storms in viral infections
- WO/2015/073804 (United States DHHS & Loyola University of Chicago, USA): Various drugs and drug candidates to prevent malaria transmission
- WO/2015/079031 (INSERM et al., Paris, France): XPO1 inhibitor drug candidates for anemia in beta-thalassemia
- WO/2015/079413 (Yeda R & D Co. Ltd., Rehovot, Israel): New mechanism for chlorhexidine and pyrvinium suggests anti-metastasis potential
- WO/2015/091857 Fondazione Istituto Italiano di Tecnologia, Genova (Italy): Loop diuretics for Down syndrome
- WO/2015/092309 (Galderma R&D, Biot, France): Naratriptan for rosacea